How have ENTO shares performed in 2024?

Entero Therapeutics' stock was trading at $2.94 at the start of the year. Since then, ENTO stock has decreased by 29.6% and is now trading at $2.07. View the best growth stocks for 2024 here .

When is Entero Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our ENTO earnings forecast .

How were Entero Therapeutics' earnings last quarter?

Entero Therapeutics, Inc. (NASDAQ:ENTO) announced its quarterly earnings results on Tuesday, May, 14th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($2.18) by $2.56.

How do I buy shares of Entero Therapeutics?

Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ENTO

Entero Therapeutics (ENTO) Stock Price, News & Analysis

→ Has Trump Finally Gone Too Far? (From Insiders Exposed) (Ad)

Free ENTO Stock Alerts

$2.07

-0.13 (-5.91%)

(As of 06/14/2024 ET)

Compare

Today's Range: $2.05
▼
$2.29
50-Day Range: N/A
52-Week Range: $1.98
▼
$39.00

Volume: 11,868 shs
Average Volume: 20,883 shs
Market Capitalization: $5.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Earnings Financials SEC Filings Trends

Get Entero Therapeutics alerts:

Ad Gold Safe Exchange

Gold Set to EXPLODE!

The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing demand from Central Banks and billionaires to EXPLODE! The elites are buying up gold like nothing we've seen before…

Click here now to download the free Precious Metals Buying Guide.

About Entero Therapeutics

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

ENTO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ENTO Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive ENTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Entero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/14/2024
Today: 6/15/2024
Next Earnings (Estimated): 8/12/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ENTO
CUSIP: N/A
CIK: 1604191
Web: www.enterothera.com
Phone: 561-589-7020
Fax: N/A
Employees: 9
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-15,800,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -102.83%
Return on Assets: -22.74%

Debt

Debt-to-Equity Ratio: 0.40
Current Ratio: 1.21
Quick Ratio: 1.21

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.31 per share
Price / Book: 0.90

Miscellaneous

Outstanding Shares: 2,480,000
Free Float: 2,463,000
Market Cap: $5.13 million
Optionable: N/A
Beta: 1.35

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. James R. Sapirstein M.B.A. (Age 63)
R.Ph., CEO & Chairman
Comp: $906.2k
Dr. Jack A. Syage Ph.D. (Age 69)
President, COO & Director
Ms. Amy Chandler-Skerkis (Age 56)
Vice President of Regulatory Affairs, QA & Compliance
Mr. Martin Krusin M.B.A.
Senior Vice President of Corporate Development

Key Competitors

View All Competitors

ENTO Stock Analysis - Frequently Asked Questions

How have ENTO shares performed in 2024?: Entero Therapeutics' stock was trading at $2.94 at the start of the year. Since then, ENTO stock has decreased by 29.6% and is now trading at $2.07.
View the best growth stocks for 2024 here.
When is Entero Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our ENTO earnings forecast.
How were Entero Therapeutics' earnings last quarter?: Entero Therapeutics, Inc. (NASDAQ:ENTO) announced its quarterly earnings results on Tuesday, May, 14th. The company reported $0.38 EPS for the quarter, beating the consensus estimate of ($2.18) by $2.56.
How do I buy shares of Entero Therapeutics?: Shares of ENTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.